Fibrate therapy in primary sclerosing cholangitis: missing data on lipids, interactions, and cancer risk
Abstract
We read with interest the study by Catanzaro et al., which evaluated the long-term safety and effectiveness of add-on fibrate therapy in primary sclerosing cholangitis (PSC) [1]. The authors provide valuable real-world data on biochemical improvements, pruritus relief, and radiological changes over a median follow-up of 34 months. However, we would like to highlight three clinically relevant aspects that were not addressed in the original study’s limitations and that merit further investigation.
Fields of Study & Subjects
Liver Diseases and Immunity
Liver Disease Diagnosis and Treatment
Inflammatory Bowel Disease
Publication details
- Journal / source
- Digestive and Liver Disease
- Publisher
- Elsevier BV
- Volume
- 58
- Issue
- 9
- Pages
- 1215–1216
- Publication date
- 30 June 2026
- Language
- EN